Filtered By:
Source: Journal of Rheumatology
Condition: Arthritis
Drug: Rituxan
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.
CONCLUSION: Abatacept and TNFi were associated with decreased risk of CVD compared to csDMARDs. Minimizing glucocorticoid use and optimizing MTX dose may improve CV outcomes in patients with RA.
PMID: 32801134 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - August 18, 2020 Category: Rheumatology Tags: J Rheumatol Source Type: research
